TWI331902B - - Google Patents
Download PDFInfo
- Publication number
- TWI331902B TWI331902B TW092121655A TW92121655A TWI331902B TW I331902 B TWI331902 B TW I331902B TW 092121655 A TW092121655 A TW 092121655A TW 92121655 A TW92121655 A TW 92121655A TW I331902 B TWI331902 B TW I331902B
- Authority
- TW
- Taiwan
- Prior art keywords
- weight
- oil
- fat
- composition
- fatty acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 62
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 28
- 229930195729 fatty acid Natural products 0.000 claims description 28
- 239000000194 fatty acid Substances 0.000 claims description 28
- 150000004665 fatty acids Chemical class 0.000 claims description 24
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 20
- 239000004615 ingredient Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 239000004519 grease Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 235000021588 free fatty acids Nutrition 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- WWKDODDYSLFNHY-UHFFFAOYSA-N [C].CCCCCC(O)=O Chemical compound [C].CCCCCC(O)=O WWKDODDYSLFNHY-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 description 53
- 235000019198 oils Nutrition 0.000 description 53
- 239000003925 fat Substances 0.000 description 52
- 235000019197 fats Nutrition 0.000 description 46
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 30
- 235000013305 food Nutrition 0.000 description 22
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 229940090949 docosahexaenoic acid Drugs 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000796 flavoring agent Substances 0.000 description 13
- 235000019634 flavors Nutrition 0.000 description 13
- 230000004913 activation Effects 0.000 description 12
- 238000012545 processing Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 239000000052 vinegar Substances 0.000 description 9
- 235000021419 vinegar Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 6
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 6
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000013373 food additive Nutrition 0.000 description 6
- 239000002778 food additive Substances 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001879 gelation Methods 0.000 description 5
- 235000013372 meat Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001766 physiological effect Effects 0.000 description 5
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 5
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940126585 therapeutic drug Drugs 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- -1 vitamin c fatty acid Chemical class 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 101150014691 PPARA gene Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 229920000223 polyglycerol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XRCRJFOGPCJKPF-UHFFFAOYSA-N 2-butylbenzene-1,4-diol Chemical compound CCCCC1=CC(O)=CC=C1O XRCRJFOGPCJKPF-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101150079778 PREP gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000242583 Scyphozoa Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229910052746 lanthanum Inorganic materials 0.000 description 2
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000003614 peroxisome proliferator Substances 0.000 description 2
- 210000002706 plastid Anatomy 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000008256 whipped cream Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical class N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102100037815 Fas apoptotic inhibitory molecule 3 Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000878510 Homo sapiens Fas apoptotic inhibitory molecule 3 Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 235000020152 coffee milk drink Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical class COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- QUSSPXNPULRXKG-UHFFFAOYSA-N galleon Natural products O1C(=CC=2)C(OC)=CC=2CCCCC(=O)CCC2=CC=C(O)C1=C2 QUSSPXNPULRXKG-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
- C11C3/10—Ester interchange
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0056—Spread compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/02—Inorganic compounds ; Elemental compounds
- C11D3/04—Water-soluble compounds
- C11D3/08—Silicates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Animal Husbandry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
Description
υζ 玖、發明說明: 【發明所屬之技術領域】 本發明係關於一種油脂组合物,其具有特定之甘油醋組 成及脂肪酸組成,風味良好且由於具有顯著之凝膠化性及 與水晶合性,放具優良之加工特性,優良之過氧化體增殖 劑活化受體aw咖eProllf⑽orActivatedRecept〇r,以 。己載為PPAR)〈活化作用,作為具p氧化活化作用之食品、 醫藥、飼料等極為有用。 【先前技術】 ,幾年’特別是對於健康維持之增進、錢之預防治療 f著高度的關心,進行多數有關魚油或其構成成分之二十 反五缔g又(C20 . 5以下以IPA記載)、二十二碳六埽酸(C22 : 6以下以DHA記載)之健康機能之研究。具體而言,被熟知 有抗動脈硬化作用、腦機能改善作用、視覺機能改善作用、 k腫瘤作用、抗發炎作用等(日本油化學會語,% ΜΗ (1999)等)^ ’ 但是此類成分於保存時之惡臭嚴重,於風味之觀點上實 用化顯著被限制。又,IPA被指出有血小板凝集抑制作用或 出血時間之延長作用。(Atherosclerosis,50, 3-10 (1984)、 Lipids,32,1 129-1136 (1997)等)。 另一方面’本發明人等發現含ΙΡΑ、〇ΗΑ之ω3系不飽和單 甘油醋、雙甘油酯具體脂肪燃燒作用(特開2〇〇1_64672號公 報)。又’單甘油酯,特別是於IPA單甘油酯中發現有高ppAR 活化作用(特開2001-354558號公報)。但是,關於DHA單甘 87245 1331902 油酯之PPAR活化作用還未被發現。 於此,所謂PPAR係核内受體之一種,為接受過氧化體增 殖劑活化之受體(Peroxisome Proliferator Activated Receptor :過氧化體增殖劑活化受體”從最近之研究得知, 此PPAR與非常多之生理、病理現象相關。即為高血脂症治 療藥之纖維酸酯(fibrate)系化合物、或作為糖尿病治療藥被 熟知惑四氫嘍唑衍生物自從被熟知為ppAR之激勵劑以 來,繼此類化合物之高血脂症或胰島素抵抗性、或糖尿病 之改善藥被試著開發(細胞,3 1 (6), 21 8-234 (1999)、J. Lipid
Res. 37, 907-925 (1996)、Curr. Opin. Lipidol. 1〇,151-159 (1999))。 其他有關於單甘油酯之各種技術亦被揭示。作為單甘油 酯之製造法被揭示於特開平3_1〇3499號公報、特開平 8-2H892號公報、特開平1G_57G_公報特開2__212588 號公報、特開2001_329291號公報等。又,於特開平'π%〗 號^報中揭示含高度不飽和脂肪酸之單甘油g旨。但是,此 類單甘油酯不論何者均有風味上之問題發生。 再者,_開平請181號公報 '特開平心⑽續公報 中揭-含單甘油醋之部分甘油醋。此些技術因以雙甘油醋 ,王要成分’與三甘油醋相較,在水中之分散性良好。但 ^ ’因早甘油时之故而無法與水混合,於加工特性上成 為問題。 · 如此明瞭含ΙΡΑ或DHA之 有各種健康機能。但是, σ工特性、風味等點上仍右 仍有問褚,現階段之技術仍未被 1331902 確立充分。 從如此之觀點而言,期待開發一種油脂組合物,作為食 品其加工特性及風味良好,並具優良生理作用。 【發明内容】 即,本發明係關於一種油脂組合物,其含有以下成分(A) 與成分(B): (A) 80〜99.9重量%之單甘油酯,其構成脂肪酸之20〜75 重量%為二十二碳六烯酸(DHA),0.1〜25重量%為二十碳五 烯酸(IPA),此等之重量比(DHA/IPA)在2以上; (B) 0.1〜20重量%之雙甘油酯。 又,本發明提供含上述油脂組合物之食品、飼料、及醫 藥品。 【實施方式】 本發明人等對關於單甘油酯之脂肪酸組成做各種探討。 其結果發現,含特定量作為構成脂肪酸之IPA及DHA之單甘 油酯混合物,其風味良好,且因具顯著之凝膠化性與與水 混合性,具優良之加工特性,且PPAR活化作用、β氧化活 化作用極強,可用以作為健康上有益之食品、飼料及醫藥 品。 構成本發明之油脂組合物之單甘油酯(成分(Α))之脂肪酸 中,DHA之含量於生理效果、加工特性、風味之點上較佳 為20〜75重量°/〇、再者為30〜65重量%、特別是35〜55重量 %為最佳。 又,構成單甘油酯(成分(Α))之脂肪酸中,ΙΡΑ之含量於生 87245 埋效果、加工特性、風味之點上較佳為〇. i〜25重量%、再 者為0_1〜20重量❶/。、特別是〇丨〜15重量%為最佳。 單甘油酯中之DHA與IPA之重量比(DHA/IPA)從風味、加 工特性、生理效果之觀點而言,必須為2以上,以2〜2〇為 佳、最好是3〜13、更好是4〜n、特別是以5〜8為最佳。 作為單甘油醋(成分(A))之殘餘之構成脂肪酸含有ω9系 不飽和脂肪酸、ω 6系不飽和脂肪酸、飽和脂肪酸等。於此 例如油酸等之碳數8〜22之ω9系不飽和脂肪酸於工業生產 性、脂肪酸之攝取平衡之觀點而言,以含有〇〜5〇重量%為 佳、再者是0.1〜25重量%、特別是〇1〜15重量%為最佳。 又,例如豆油酸、γ-亞麻酸等之碳數8〜22之ω 6系不飽 和脂肪酸於工業生產性、脂肪酸之攝取平衡之觀點而言, 以含有0.1〜25重量%為佳、再者是〇丨〜1〇重量%、特別是 0.2〜5重量%為最佳。 再者,飽和脂肪酸於工業生產性、生理效果之觀點而言, 以含有0〜30重量%為佳、再者是〇」〜2〇重量%、特別是〇 5 〜1 5重量為最佳β 茲單甘油酯(成分(Α))於生理效果 '加工特性之觀點而 τ,於本發明之油脂組合物中以含有8〇〜99 9重量%為必 要、以90〜99重量%為佳、再者是92 9〜97重量%、特別是 93〜97重量%為最佳。 雙甘油酯(成分(B))於加工特性、工業生產性、風味之觀 點而5,於本發明之油脂组合物中以含有〇 .丨〜2〇重量%為 必要、以1〜10重量%為佳、再者是2 9〜7重量%、特別是3 87245 -9· 7重量%為最佳。 二雙甘油酯(成分⑻)之構成脂肪酸與單甘油酯之相同,惟 就工業之生產性而言較佳。 於本發明之油脂組合物中,三甘㈣之含有量於加工特 性、生理效果、工業生產性之觀點而言,以含有19 9重量% 以下為佳、再者是0〜9重量%、特別是0.01〜4重量%、更 特殊以0.1〜4重量。/。為最佳。 三甘油醋之構成脂肪酸與單甘油醋之自同"淮就工業之 生產性而言較佳。 於本發明之油脂組合物中,游離脂肪酸或其鹽之含有量 於風味、安疋性、工業生產性之觀點而言,以含有5重量% 以下為佳、再者是〇〜2 5重量%、特別是〇 〇1〜丨重量%、更 特殊以0.1〜0 5重量%為最佳。 二本?明之油脂組合物中之游離脂肪酸或其鹽之構成脂肪 酸與單甘油自旨之相同處’係就工業之生產性而言較佳。 具如此之特定甘油酯組成及脂肪酸組成之本發明之油脂 组合物,例如可依使用脂酶等酵素之甘油及與脂肪酸之酯 化反應、或使用鹼觸媒等之甘油與油脂之酯交換反應製 ^又,依後述製造例所示,將二氧雜戊環等保護基與甘 油結合後進行油脂與酯交換反應,之後利用去除其保護基 可製造目的之油脂組合物。 本發月之油脂組合物貫施脫膠 '脫酸 '水洗、脫色、脫 臭等精製而加以使用,就風味、安定性而言為佳,特別是 過氧化物價(P〇V)於20以下,較佳是1〇以下,更佳是7以下, 87245 1331902 再更佳是5以下,特佳是3以下 付住疋J以下,最佳是0.1〜1。再者,利 用k維邦法(使用5.25英吋之 4 <坡螭容器)之顏色(1〇 R+Y)以 万;5〇以下,較佳是4〇以 0 θ 又佳疋30以下,特別是5〜25為 瑕佳。 '本發明之油脂組合物中添加抗氧化劑(成分(〇)於風 女疋性之點為佳。抗氧化劑通常只要是被使用於食品、 醫樂^任一者即可。以兒茶酸、生育盼'維他命c脂肪酸脂、 •^工基甲苯(BHT)、丁基幾基菌香_ (BHA)、第三丁基氫 酉昆⑽叫)、磷脂質、天然抗氧化成分之!種或2種以上之組 合為佳,特別是以生育⑯、兒茶酸為佳1為維他命c脂肪 ㈣可舉例棕櫚酸醋、硬脂酸酉旨,作為天然抗氧化成分可 舉例迷迭香等之藥草、桃葉、根塊等之萃取物等。抗氧化 ,於本發明之油脂組合物中添加〇 gi〜5重量。4為佳、特別 是0_05〜1重量%為佳。 本發明之油脂組合物於膽固醇下降之效果上,以含有植 物巢醇(成分⑽為佳。植物⑽於本發明之油脂組:物中 =含有0.05〜i 9.9重量%為佳、再者為〇 3〜4 7重量%、特別 是h2〜4·7重量%。於此作為植物巢醇可舉例cc-谷巢醇、β_ 谷巢醇、i巢醇、菜油巢醇、α_谷巢燒醇' β谷巢燒醇、 stlgmastaro卜campestar〇卜環阿頓醇等之自由體、及此類 之脂肪酸酯、阿魏酸酯、桂皮酸酯等之酯類等。 於本發明之油脂組合物中再添加油脂抑制劑於外觀、作 業之點上為佳。作為本發明使用之結晶抑制劑可舉例聚甘 油縮合甘油三W醇酸醋 '聚甘油醋肪酸酷、薦糖脂肪酸 87245 1331902 醋、山梨糖醇酸奸脂肪酸醋、聚乙二醇山梨糖醇酸奸脂肪 酸點、丙知乙二醇脂肪酸醋之聚醇脂肪酸酯等。又,聚 脂肪酸酿HLB (Gnffln之計算式)在4以下,特別是以^下 之聚甘油醋肪酸醋、薦糖脂肪酸酷、山梨糖醇酸奸脂肪酸 酉旨域。於本發明之油脂組合物中結晶抑制劑以含有⑽ 5重量/〇,特別是〇·〇5〜2重量%為佳。 如此而得之油脂組合物具極優良之ppAR活化作用、_ 化活化作用’再者由於具良好之凝膠化性及膨潤性且優良 之加工特性以及風味。因具如此優1之特性,本發明之·.由 脂組合物可利用於食品、飼料及醫藥品。 、作為食品’可使用於將含有該油脂組合物為食品一部分 ,油脂含有食品或油脂添加物中。作為如此之油脂含有食 了’例如可發揮特定之機能舉例可圖增進健康之健康食 口口。又,作為食品添加物於乳化、去乳化、可溶化、分散、 濕潤、被覆、起泊、消冶 、·^ .45·, . a 4泡次透、離型、洗淨 '抗菌、品 質改良等之目的上,作A & Μ 作為札化劑'品質改良劑等可補助性 地於食品中使用。 為八fla之& 可舉例為摻合此油脂組合物之膠囊、藥 鍵、顆粒劑、粉末劑、麵包、蛋糕、餅乾、派、比薩皮、 w合烘给寺烘培食品;#、調味料、冰澳淋、咖啡奶球、 ^4乃a '打泡奶油等之水中油型乳化食品;人造 由塗抹奶油、含糖奶油等之油中水型乳化食品;巧克 ’二果牛奶糖 '糖果叙等點心丨香腸、火腿、漢堡等 肉加工食品,其他亦可舉例飲料、麵、蔬菜、冷;束食品、 87245 •12· 1331902 农裝食品等。此食品除上述油脂組合物外,應油脂含有食 或食品添加物之種類,可添加—般可用於食品添加之食 品原料而加以製造。 於本發明之油脂組合物脂油脂含有食品之添加量會隨食 之種類不同,一般以0丨〜100重量%、特別是8〇重量 /〇為佳。又’於本發明之油脂組合物之食品添加量中之摻 合!儘管依食品添加物之用途而不同,一般以i〜1〇〇重量 /〇特別是80〜1 00重量。/()為佳。於本發明之食品添加物之 食品中之摻合量儘管依食品添加物之用途而不同,一般以 0·01〜10重量%、特別是〇.1〜5重量%為佳。 作為醫藥品例如可使用粉末、顆粒、膠囊、藥丸、藥錠 等固型製劑;水劑、懸浮劑、乳化劑等液劑等經口投藥劑 伙此、’二口彳又藥劑除上述油脂組合物外,應經口投藥劑之 型怨可添加一般被使用之賦形劑、崩壞劑、結合劑、滑澤 劑、界面活性劑、醇類、水、水溶性高分子、甜味料、調 味劑、酸味料等而製造。作為經口投藥用醫藥品基於ppaR 活化作$、β氧化活化作用可舉例糖尿病預防治療藥、肥胖 預防治療藥、高血脂症預防治療藥等。於本發明之油脂組 ::之經口投藥用醫藥品之摻合量儘管依醫藥品之用途及 型態而不同,一般以0.1〜1⑼重量%、特別是1〜80重量% 為佳。又,投藥量作為油脂組合物以一天〇 1〜〇 g,一天 投藥一至數回為佳。 87245 作為飼料,並非只是豬、雞、魚等動物用飼料,亦可列 舉犬、貓寺寵物用寵物食品β於本發明中之油脂組合物飼 •13- 科十之接合量以!〜4〇重量%、再 2〜20重量%為佳。本,,· !%、特別是 部、或油脂之-部分脂組合物可置換飼科中之全 類此=科於上迷油脂组合物中,可與肉類、蛋白質、穀物 ;;糠類'糟相類、糖類、蔬 : 飼料原料—同相人 质物男類寺 肉咬小羊 °作為_可舉例牛、豬、羊(羊 肉粉、肉:/袋藏等畜肉、獸肉及其副生物、加工品; 竹二二上述原料之提取物;歸魚、松魚、 白μ y…/母扇、海螺、魚粉等魚貝類等。作為蛋 物:2例=白、乳清等乳蛋白質或大豆蛋白質等之植 貝,作為穀物類可舉例小麥、大麥、黑麥、麥路、 舉例大:相'為米糠類可舉例米糠、麥糠等;作為相類可 柄類之合計量:?中<肉類、蛋白質、縠物類'米糠類、 糖、多_、^〜95重1%為佳。作為糖類可舉例葡萄 8〇重量。/:為:糖、糖栽:殿粉、液糖等,飼料中以含有5〜
。〜。作為蔬菜類可舉例蔬菜精,於飼料中以各 • 董里/°為佳。作為維他命可舉例A、β 1、β 2、D 意/、酸、之酸、胡蘿蔔素等’於飼料中以含有G.G5〜10重 里為佳。作為礦物質類可舉例鈣、磷、鈉、鉀 '鐵、鎂、 ^錯等,於飼料中以含有〇.〇5〜1〇重量%為佳。其他方^ :使用—般於飼料中被使用之凝膠化劑、保型劑、PH調整 二、凋味料、防腐劑、營養劑、補強劑等。 實施例 貝施例1油脂組合物之製造 87245 -14- 1331902 製造以下之油脂組合物。所得之油脂組合物組成如表i 所示。單甘油酯組成依HPLC法測定(管拄:「TSKgelG25〇〇H」 TOSO(股)製、溶出溶劑:THF、溶劑流速:〇 4 mL/分、檢 測器:RI)。脂肪酸組成於甲基酯化後依GLC法測定(日本油 化學協會「基準油脂分析試驗法」2.4.1.2-1996、 2.4.2.2-1996)。 油脂組合物1 (本發明品) 於四口燒瓶中加入2,2-二甲基-1,3 -二氧雜戊環-4-甲醇 422.9 g與氫氧化鈉0.64 g’於8〇t下進行減壓脫水與醇鹽化 後,於50°C下冷卻。於此中添加DHA高量含有油「DHA-22」 (MARUHA(公司)製)355.3 g進行u小時反應後,於5〇%硫 酸中進行中和反應。其次,於1.33 kPa、80〜100t:下進行 減壓崧餾,將水與2,2-二甲基_ 1,3-二氧雜戊環_4_曱醇蒸餾 去除。將此水洗而得縮醛單甘油酯45 1.4 g。 於所得之220 g縮醛單甘油酯中加入丨3 2克酸性高嶺土 (Galleon Earth NV、水澤化學(公司)製)。於反應系統内每 小時對於縮醛單甘油酯導入10%水蒸氣’邊將於反應時生 成之丙酮與過剩之水蒸氣除去至系統外,進行6小時之脫縮 越化反應(70t、丨3.3 kPa)e其次,加入66 §酸吸附劑 (KW600S、協和化學(公司)製)後,進行〇 5小時脫水(6 65 kPa、7〇°〇。將此過濾,可得17〇 7 §單甘油酯。於此中加 入2〇〇Ppm生育驗「EMIXD」(EISAI (公司)製),製造油脂 組合物1。 油脂組合物2 (本發明品) 87245 -15- 1331902 作為DHA高量含有油,使用「dhA-45」(MARUHA公司 製),以與油脂組合物1相同之方式製造油脂組合物2。 油脂組合物3 (本發明品) 於四口燒瓶中加入1000 g之DHA高量含有油「DHA-70G」 (日本化學飼料(公司)製)、28〇 g之甘油酯與1 §之氫氧化 鈉,於氮氣氣流下於1 70°C下反應2小時。於反應終了後加 入0.8 8 g磷酸加以中和。其次,進行1〇分鐘脫甘油酯(18〇 C、0.667 kPa)後’進行薄膜蒸餾(185〇c、〇 〇〇4 kPa)。採 取於薄膜蒸餾後留下之餾分,於此中加入2〇〇 ppm生育酚 rEMIX D」(EISAI (公司)製),而得油脂組合物3。 油脂組合物4 (比較品) 作為油脂組合物4,使用DHA高量含有油「DHA-22」 (MARUHA公司製)。 油脂組合物5 (比較品) 採取於製造油脂組合物3時生成之薄膜蒸餾之殘餾液。將 此於矽膠色層分析(r WAK〇凝膠C 2〇〇」(和光純藥(公司) 製)中’作為溶劑使用己烷與醋酸乙酯(最初丨〇〇 : 〇、其次95 : 5、其次90 : 1〇 '其次8〇 : 2〇、最後7〇 : 3〇、v/v)之分割。 其次,溶劑使用蒸餾器去除。將所得之各分層混合後,加 入2〇〇Ppm生育酚「EMIXD」(EISAI (公司)製),製造出油 脂組合物5。 油脂組合物6 (比較品) 作為油脂組合物6,使用高純度單甘油酯「ekisel 0-95R」 (花王(公司製))。 87245 -16- 1331902 油脂組合物7 (比較品) 使用「eicosapentaenoic acid」(Sigma公司製)。 油脂組合物8 (比較品) 使用「docosahexaenoic acid」(Sigma公司製)。 實施例2 PPARj活化試驗 將小腸上皮細胞病株IEC-6散佈於12焊接盤上,於DMEM (5% FCS)中培養一日。於此中,將發現GAL4-DNA結合區 域(DBD)與PPARj配位體結合區域(LBD)之嵌合體分子之質 體(pGAL4-PPARY-LBD)、與於螢火蟲螢光素酶基因之上流 中含有GAL4結合配列之通訊質體(pREP)以同時各自呈〇.5 pg/well之狀態,利用轉換感染試藥(Superfect transfection reagent ; QIAGEN)加以導入。又,為監控轉換感染效率, 於pGAL4-PPARj-LBD5中同時編入水母螢光素酶基因。其 後,將培養液與含被驗物質(500 μΜ)之DMEM (+250 μΜ BSA)培地交換,再培養24小時。於PBS洗淨後,使用Dual 螢光素酶化驗系統(Promega)將細胞溶解。其次,於該溶解 液中加入含蟲螢光素之基質溶液,利用光度計分別測定螢 火蟲及水母之螢光素酶活性。如此利用測定PPARy之依存性 基因之轉錄活性(螢光素酶活性)以評價PPARj活化能。又, PPARY之依存性轉錄活性(螢光素酶活性)如以下之定義。 ΡΡΑΙΙγ之依存性基因之轉錄活性(螢光素酶活性)=(由於 pREP之營火蟲勞光素酶活性)/(由於pGAI^-PPARj-LBD之 水母勞光素酶活性)。 又,將對照組之ΡΡΑΙΙγ依存性轉錄活性設定為1 p〇,對於 87245 -17- 1331902 其之相對值顯示於表1中。 實施例3 凝膠化性之評價 於备油脂 个(莖重/重量)之 並如睨办以m个 h況下用目視觀察 其视胗化性,用下述評價基準執行評價。 Λ . ^ .. . 、/、結果如表1所示。 A ·播流動性’呈凝膠狀態。 B :幾乎無流動性,稍呈凝膠狀態。 C :具流動性,—部份呈凝膠狀態。 D :具流動性,不呈凝膠狀態。 貫施例4 惡臭之評價 將於實施例3中製作之樣品試料(各 吉,,田下鸪罟A 知.水=70 : 30)於 置一週。嗅其臭味’並依下述基準進行惡臭之官 此坪價。結果如表1所示0 A :幾乎無惡臭,無不快感。 B :稍有惡臭,幾乎無不快感。 C :有惡臭,有不快感。 . D :有強烈惡臭,有非常不快感。 實施例5與水混合性之評價 於50°C下’於加溫之各樣品試料中以每$重量%調查於全 系統中其可混入至多少重量%為止之水。取水分離前之一 點為其與水混合性之值。結果如表1所示。 87245 •18- 1331902 表1 本發明t 口 V 圼! /〇 ; 比較品 油脂組合物號碼 1 2 3 4 5 6 7 8 油W TG 0 0 0 96.3 15.5 0 0 0 脂 DG 7 5 2 1.2 83.7 7.9 0 0 組 MG 93 94.9 96.4 0.5 0.8 92.1 0 0 成 FFA 0 0.1 1.6 0 0 0 100 100 C16 : 0 17 9.9 3.2 17 2.6 5.5 ND ND C16 : 1 ' 4.7 3.5 ND*2 4.7 0.5 0.3 ND ND 脂 C18 : 0 4.1 2 ,1.7 4.1 1.5 4.1 ND ND 肪 C18 : 1 22.6 11.1 0.3 22.6 0.3 69.9 ND ND 酸 C18 : 2 1 1.6 0.7 1 0.6 14.2 ND ND 組 C20 : 1 2.9 1.6 1.2 2.9 1.1 1.8 ND ND 成 C20 : 5 6.3 6.7 6.3 .6.3 5.9 ND 99 ND C22 : 5 1.6 2.4 1.2 1.6 1.6 ND ND ND C22 : 6 24 41.3 63.7 24 67.2 ND ND 98 DHA/IPA 3.8 6.2 10.1 3.8 11.4 加 PPARy 233 535 488 141 129 135 480 508 工 凝膠化性 B A〜B A D D B D D 特 惡臭 B A〜B A C D A D D 性 與水混合性 20 25 35 0 0 10 - • * 1 :油脂組成TG ;三甘油酯、DG ;雙甘油酯、MG ;單甘 油酯、FFA ;游離脂肪酸 #2 : NG ;未檢測 87245 -19-
Claims (1)
1331902 第092121655號專利申請案 -- 中文申請專利範圍替換本(96年9月1& ^ jL 拾、申請專利範園: L __ 1 · 一種油脂組合物,其係含有以下成分(A)與成分(B): (A) 80〜99.9重量%之單甘油酯,其構成脂肪酸之2〇 65重·®· /〇為一十二碳六晞酸(DHA),0.1〜15重量%為 二十碳五晞酸(IPA),此等重量比(DHA/IPA)在3〜13 ; (3)0.1〜20重量%之雙甘油酯; 及5重量。/。以下之游離脂肪酸。 2·如申請專利範圍第1項之油脂組合物,其中再含有(C)抗 氧化劑0.01〜5重量%。 3. 如申4專利範圍第1或2項之油脂組合物,其中再含有(D) 植物巢醇〇.〇5〜19.9重量%。 4. 一種食品,其含有如申請專利範圍第丨〜3項中任一項之 油脂組合物。 5. 種飼料,其含有如申請專利範圍第1〜3項中任一項之 油脂組合物。 6. 種糖尿病、高血脂症、肥胖用之醫藥組合物,其含有 如申請專利範圍第1〜3項中任_項之油脂組合物。 87245-960907.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002229901 | 2002-08-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200407080A TW200407080A (en) | 2004-05-16 |
TWI331902B true TWI331902B (zh) | 2010-10-21 |
Family
ID=31943813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092121655A TW200407080A (en) | 2002-08-07 | 2003-08-07 | Fat composition |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1544281B1 (zh) |
KR (1) | KR100951758B1 (zh) |
CN (1) | CN1309813C (zh) |
AU (1) | AU2003252324A1 (zh) |
TW (1) | TW200407080A (zh) |
WO (1) | WO2004018598A1 (zh) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040209953A1 (en) * | 2002-12-06 | 2004-10-21 | Wai Lee Theresa Siu-Ling | Glyceride compositions and methods of making and using same |
SE0303513D0 (sv) | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
WO2006074089A2 (en) * | 2004-12-30 | 2006-07-13 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
US8252742B2 (en) | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
US8324276B2 (en) | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
AU2006242914B2 (en) | 2005-05-04 | 2012-02-02 | Pronova Biopharma Norge As | New DHA derivatives and their use as medicaments |
CN101213281B (zh) * | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | 新的dha衍生物及其作为药物的用途 |
WO2008012106A1 (en) * | 2006-07-28 | 2008-01-31 | Bioriginal Food & Science Corporation | Fat containing composition |
KR100684642B1 (ko) * | 2006-09-14 | 2007-02-22 | 주식회사 일신웰스 | 어유 유래 글리세라이드 유지 조성물 및 이의 제조방법 |
MX2009004336A (es) * | 2006-11-01 | 2009-05-22 | Pronova Biopharma Norge As | Lipidos omega-3 alfa-sustituidos que son activadores o moduladores del receptor activado por proliferadores de peroxisoma (ppar). |
RU2507193C2 (ru) * | 2006-11-01 | 2014-02-20 | Пронова Биофарма Норге А/С | Альфа-замещенные омега-3 липиды, которые являются активаторами или модуляторами рецептора, активируемого пролифераторами пероксисом (ppar) |
EP2102139A2 (en) * | 2006-11-01 | 2009-09-23 | Pronova Biopharma Norge AS | Omega-3 lipid compounds |
RU2009121007A (ru) * | 2006-11-03 | 2010-12-10 | Пронова Биофарма Норге Ас (No) | Жирные спирты |
KR100856456B1 (ko) * | 2007-07-27 | 2008-09-04 | 주식회사 일신웰스 | 면역 증강용 사료 첨가제 및 이를 포함하는 가축 사료 |
JP5711968B2 (ja) | 2007-10-03 | 2015-05-07 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーE.I.Du Pont De Nemours And Company | 高エイコサペンタエン酸を生成するためのヤロウィア・リポリティカ(YarrowiaLipolytica)の最適化株 |
US20090182049A1 (en) * | 2008-01-16 | 2009-07-16 | Joar Arild Opheim | Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans |
CA2771478A1 (en) * | 2009-08-26 | 2011-03-03 | Epax As | Antioxidant composition |
JP5700503B2 (ja) * | 2009-09-07 | 2015-04-15 | 日清オイリオグループ株式会社 | グリセリド組成物及び該グリセリド組成物の製造方法 |
CN103260422A (zh) * | 2010-12-20 | 2013-08-21 | 希尔氏宠物营养品公司 | 用于诱导饱食反应的宠物食品组合物 |
ES2845556T3 (es) * | 2011-11-01 | 2021-07-27 | Dsm Ip Assets Bv | Aceite que contiene ácidos grasos poliinsaturados estable oxidativamente |
DK3384902T3 (da) | 2012-02-17 | 2021-01-18 | Alcresta Therapeutics Inc | Fremgangsmåder, sammensætninger og indretninger til opfyldelse af diætmæssige behov for fedtsyre |
CN103445162B (zh) * | 2013-08-21 | 2015-08-26 | 华南理工大学 | 一种丙酮酰基月桂酰基甘油酯及其制备方法 |
CN104543037A (zh) * | 2015-01-06 | 2015-04-29 | 陶醒世 | 健脑营养油 |
US10258590B2 (en) | 2015-10-14 | 2019-04-16 | Alcresta Therapeutics, Inc. | Enteral feeding device and related methods of use |
JP2020503388A (ja) * | 2016-12-23 | 2020-01-30 | ビーエーエスエフ エーエス | 悪液質を予防及び/又は処置するためのオメガ−3脂肪酸組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03103499A (ja) * | 1989-09-14 | 1991-04-30 | Meito Sangyo Kk | 高度不飽和脂肪酸モノグリセリドの製造方法 |
JPH1057086A (ja) * | 1996-08-20 | 1998-03-03 | Asahi Chem Ind Co Ltd | 高濃度ドコサヘキサエン酸モノグリセリドの製造方法 |
CN1125596C (zh) * | 1998-03-24 | 2003-10-29 | 花王株式会社 | 含有植物甾醇的油脂组合物 |
JP2001064672A (ja) * | 1999-08-26 | 2001-03-13 | Kao Corp | 体脂肪燃焼促進剤 |
JP4391673B2 (ja) * | 2000-08-08 | 2009-12-24 | 花王株式会社 | 油脂組成物 |
-
2003
- 2003-08-01 EP EP03792646.6A patent/EP1544281B1/en not_active Expired - Fee Related
- 2003-08-01 KR KR1020057001626A patent/KR100951758B1/ko active IP Right Grant
- 2003-08-01 AU AU2003252324A patent/AU2003252324A1/en not_active Abandoned
- 2003-08-01 CN CNB038191512A patent/CN1309813C/zh not_active Expired - Fee Related
- 2003-08-01 WO PCT/JP2003/009806 patent/WO2004018598A1/ja active Application Filing
- 2003-08-07 TW TW092121655A patent/TW200407080A/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1309813C (zh) | 2007-04-11 |
EP1544281B1 (en) | 2016-10-05 |
AU2003252324A1 (en) | 2004-03-11 |
KR20050026536A (ko) | 2005-03-15 |
KR100951758B1 (ko) | 2010-04-08 |
WO2004018598A1 (ja) | 2004-03-04 |
EP1544281A4 (en) | 2005-12-28 |
TW200407080A (en) | 2004-05-16 |
CN1675344A (zh) | 2005-09-28 |
EP1544281A1 (en) | 2005-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI331902B (zh) | ||
RU2376782C2 (ru) | Масляная композиция и содержащие ее пищевые продукты, фармацевтическая композиция и пищевая добавка | |
EP1307108B1 (en) | Oil/fat composition | |
US7410663B2 (en) | Oil or fat composition | |
US20030054082A1 (en) | Oil or fat composition | |
JP2002138297A (ja) | 油脂組成物 | |
JP2008069184A (ja) | 油脂組成物 | |
KR20040095263A (ko) | 체온상승제 | |
WO2005027892A1 (ja) | インスリン初期分泌促進剤 | |
JP6896417B2 (ja) | クリルオイルと魚油とシソ油とを含有する組成物 | |
JP4268473B2 (ja) | 油脂組成物 | |
US20030086981A1 (en) | Glycerin fatty acid ester for palliate a symptom of premenstrual syndrome, a palliative of premenstrual syndrome, oil or fat composition for palliate a symptom of premenstrual syndrome, and food and drink for palliate a symptom of premenstrual syndrome | |
JP4783550B2 (ja) | 大腸ガン抑制剤及びそれを含む食品 | |
JP7356833B2 (ja) | 末梢体温亢進剤 | |
JP4594489B2 (ja) | 特異的殺癌細胞剤及びこれを配合してなる組成物 | |
JPWO2004064830A1 (ja) | 生活習慣病予防・改善用の油脂加工組成物 | |
JP2000239168A (ja) | 脳卒中予防剤およびこれを配合してなる組成物 | |
JP4469407B1 (ja) | 血中中性脂肪低下剤 | |
JP2024051305A (ja) | 糖質燃焼促進剤 | |
JP2021052782A (ja) | クリルオイルと魚油とシソ油とを含有する組成物 | |
US20040259947A1 (en) | Glycerin fatty acid ester for palliate a symptom of premenstrual syndrome, a palliative of premenstrual syndrome, oil or fat composition for palliate a symptom of premenstrual syndrome, and food and drink for palliate a symptom of premenstrual syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |